EyePoint Pharmaceuticals
Présence
EyePoint Pharmaceuticals fait partie des...
EyePoint Pharmaceuticals est une société cotée sous le symbole boursier EYPT (US).
Acquisition, funding and merger involving EyePoint Pharmaceuticals.
- EyePoint Pharmaceuticals vient d'annoncer une levée de fonds de 115 millions de dollars. (publié le 24 novembre 2021).
Dirigeants
Voir l'organigramme avec ses 19 principaux dirigeants
Biographies les plus recherchées chez EyePoint Pharmaceuticals
- Nancy Lurker, President, Chief Executive Officer and Director
- Wendy DiCicco, Director
- Victor Liu, Director
Changements de dirigeants chez EyePoint Pharmaceuticals
- Tony Adamis, a rejoint l'entreprise comme Director (publié le 23 juin 2022).
- Isabelle Lefebvre, a rejoint l'entreprise comme Chief Regulatory Officer (publié le 8 mars 2022).
- Michael Pine, a rejoint l'entreprise comme Chief Corporate Development and Strategy Officer (publié le 11 janvier 2022).
Cliquez ici pour voir d'autres changements chez EyePoint Pharmaceuticals
Créer une alerte
pour suivre les mouvements de dirigeants chez EyePoint Pharmaceuticals.
Équipements médicaux
EyePoint Pharmaceuticals a 956 concurrents dont Philips (Pays—Bas), Medtronic (Irlande) et Thermo Fisher Scientific (Etats—Unis).
Actualités en fusion/acquisition en Équipements médicaux.
- MicroTransponder vient d'annoncer une levée de fonds de 53 millions de dollars. (publié le 21 juin 2022).
- BD has announced the acquisition of Parata Systems (publié le 8 juin 2022).
- Halozyme Therapeutics a acquis Antares Pharma (publié le 24 mai 2022).
Contacts en Équipements médicaux
Actualités
Derniers communiqués de presse par EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of Directors | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China’s NMPA for YUTIQ® for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals to Present 12-Month Results from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD at the American Society of Retina Specialists 2022 Annual Meeting | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals to Present at the H.C Wainwright Global Healthcare Investment Conference | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Announces Expanded License Agreement with Betta Pharmaceuticals for EYP-1901 in China, Hong Kong, Macau and Taiwan | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Developments | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022 | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting | EyePoint Pharmaceuticals
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- EyePoint Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Nancy Lurker 
Appelez EyePoint Pharmaceuticals au +1 617...
